Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms
暂无分享,去创建一个
Olivier Hermine | M. Vidaud | P. Dubreuil | O. Hermine | O. Lortholary | M. Arock | F. Féger | Y. Zermati | Michel Vidaud | Michel Arock | Yael Zermati | Paulo De Sepulveda | Frederic Féger | Sebastion Létard | Joelle Kersual | Nathalie Castéran | Guy Gorochov | Michel Dy | Antoni Ribadeau Dumas | Karim Dorgham | Christophe Parizot | Yann Bieche | Olivier Lortholary | Patrice Dubreuil | G. Gorochov | C. Parizot | K. Dorgham | M. Dy | J. Kersual | N. Castéran | P. D. Sepulveda | Sebastion Létard | Yann Bieche
[1] P. Peterlongo,et al. C-kit mutations in core binding factor leukemias. , 2000, Blood.
[2] Yukihiko Kitamura,et al. Decrease of mast cells in w/wv mice and their increase by bone marrow transplantation. , 1978 .
[3] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[4] T. Jacks,et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.
[5] D. Heitjan,et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[6] T. Duffy,et al. The mast cell and mast cell disease. , 1995, Journal of the American Academy of Dermatology.
[7] W. Vainchenker,et al. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7 , 2000, Leukemia.
[8] T. Kaisho,et al. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. , 1999, Blood.
[9] T. Naoe,et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.
[10] Y. Matsuzawa,et al. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. , 1996, Blood.
[11] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[12] A. Worobec. Treatment of systemic mast cell disorders. , 2000, Hematology/oncology clinics of North America.
[13] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[14] K. Zsebo,et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. , 1992, Blood.
[15] K. Lennert,et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.
[16] M. Triggiani,et al. Treatment of mastocytosis: pharmacologic basis and current concepts. , 2001, Leukemia research.
[17] P. Valent,et al. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. , 2001, Leukemia research.
[18] D. Birnbaum,et al. Phosphatidylinositol-3′ Kinase Is Not Required for Mitogenesis or Internalization of the Flt3/Flk2 Receptor Tyrosine Kinase* , 1996, The Journal of Biological Chemistry.
[19] G. Dewald,et al. Establishment of an immature mast cell line from a patient with mast cell leukemia. , 1988, Leukemia research.
[20] O. Hermine,et al. TGF-beta1 drives and accelerates erythroid differentiation in the epo-dependent UT-7 cell line even in the absence of erythropoietin. , 2000, Experimental hematology.
[21] B. Longley,et al. A proposed classification of mastocytosis incorporating molecular genetics. , 2000, Hematology/oncology clinics of North America.